On August 9, 2022, the BSA Future Star Award, which was initiated and jointly hosted by the 2nd China International Vaccine Innovation Summit and Industry Panelists, came to a perfect conclusion. After furious competition, 10 companies entered the final competition and the final winner got unveiled. METiS Pharmaceuticals, is honored to bag the BSA Future Star Award.
METiS Representative in Awards Presentation
Best Start-Up Awards (BSA) is focusing on vaccine industry since its initiation of the first China International Vaccine Innovation Summit in 2021, it is also knowns as an appraisal competition among those vaccine start-ups in China. BSA is gathering the KOLs, dark horses in vaccine business, and industry leading media together, tracking the business case in vaccine industry with in-depth insights. With the focus on the scientific definition of business model in vaccine area, team, technical direction, investment potential, etc., and with the purpose of establishing the evaluation system for vaccine industry start-ups, BSA is to comprehensively evaluate the innovation capability, business model, team, technical capability and development prospects of Chinese vaccine enterprises.
BSA aims to praise the best ‘entrepreneurship and innovation’ paradigms of Chinese vaccine start-ups, so as to foster the transformation of commercial innovation from scientific research achievement, and to provide investment guidance with high reference value for domestic and foreign investors.
METiS Pharmaceuticals (METiS), as a biotechnology company, has been persistent in bring best-in-class therapies across a broad spectrum of diseases, by combining drug delivery &discovery with AI, machine learning, and quantum simulation, to ultimately address unmet clinical needs.
The integration of AI, quantum simulation and high-throughput experimental platform and other interdisciplinary technologies enables METiS to build the unique AiLNP, AiRNA and AiTEM core technology platforms to predict the physical, chemical and biological characteristics of small molecules and nucleic acid drugs in a specific micro-environment. By virtue of AI iterations from dry and wet experiment, METiS has achieved more effective innovative delivery material design, nucleic acid sequence design and optimization, and has designed more advantageous formulation or nucleic acid-based delivery system.
